Haematologica (Aug 2012)

Evaluation of prognostic factors among patients with chronic graft-versus-host disease

  • Jose A. Pérez-Simón,
  • Gabriel Afram,
  • Rodrigo Martino,
  • Jose L Piñana,
  • Teresa Caballero-Velazquez,
  • Olle Ringden,
  • David Valcarcel,
  • Dolores Caballero,
  • Mats Remberger,
  • Yanira de Paz,
  • Jordi Sierra,
  • Jesús San Miguel,
  • Hans Hagglund

DOI
https://doi.org/10.3324/haematol.2011.055244
Journal volume & issue
Vol. 97, no. 8

Abstract

Read online

Background Chronic graft-versus-host disease (cGVHD) is a major complication after allogeneic stem cell transplantation with an adverse effect on both mortality and morbidity. In 2005, the National Institute of Health proposed new criteria for diagnosis and classification of chronic graft-versus-host disease for clinical trials. New sub-categories were recognized such as late onset acute graft-versus-host disease and overlap syndrome.Design and Methods We evaluated the prognostic impact of the new sub-categories as well as the clinical scoring system proposed by the National Institute of Health in a retrospective, multicenter study of 820 patients undergoing allogeneic stem cell transplantation between 2000 and 2006 at 3 different institutions. Patients were retrospectively categorized according to the National Institute of Health criteria from patients’ medical histories.Results As far as the new sub-categories are concerned, in univariate analysis diagnosis of overlap syndrome adversely affected the outcome. Also, the number of organs involved for a cut-off value of 4 significantly influenced both cGVHD related mortality and survival. In multivariate analysis, in addition to NIH score, platelet count and performance score at the time of cGVHD diagnosis, plus gut involvement, significantly influenced outcome. These 3 variables allowed us to develop a simple score system which identifies 4 subgroups of patients with 84%, 64%, 43% and 0% overall survival at five years after cGVHD diagnosis (score 0: HR=15.96 (95% CI: 6.85–37.17), P